Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy

Pediatrics

Volumn 124, Issue 2, 2009, Pages

  Zhu, Changlian ^a,b   Kang, Wenqing ^c   Xu, Falin ^a,b   Cheng, Xiuyong ^a,b   Zhang, Zhan ^a,b   Jia, Liting ^a,b   Ji, Ling ^a   Guo, Xiaoyan ^a   Xiong, Hong ^c   Simbruner, George ^d   Blomgren, Klas ^e,f   Wang, Xiaoyang ^a,b  

^a ZHENGZHOU UNIVERSITY   (China)

^b Henan Key Laboratory for Neonatal Brain Injury   (China)

^c ZHENGZHOU CHILDREN S HOSPITAL   (China)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Asphyxia; Erythropoietin; Hypoxic ischemic encephalopathy; Neonates

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BLOOD ANALYSIS; BRAIN ISCHEMIA; CEREBROSPINAL FLUID LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DEVELOPMENT; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VEIN THROMBOSIS;

ASPHYXIA NEONATORUM; BRAIN DAMAGE, CHRONIC; CHINA; DEVELOPMENTAL DISABILITIES; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTENSIVE CARE UNITS, NEONATAL; MALE; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; PSYCHOMOTOR DISORDERS;

EID: 67749137294     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2008-3553     Document Type: Article

References (45)

1. Johnston MV, Nakajima W, Hagberg H. Mechanisms of hypoxic neurodegeneration in the developing brain. Neuroscientist. 2002;8(3):212-220
2. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005;353(15):1574 -1584
3. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365(9460):663- 670
4. Gunn AJ, Gunn TR, Gunning MI, Williams CE, Gluckman PD. Neuroprotection with prolonged head cooling started before postischemic seizures in fetal sheep. Pediatrics. 1998;102(5): 1098 -1106
5. Silverman WA, Fertig JW, Berger AP. The influence of the thermal environment upon the survival of newly born premature infants. Pediatrics. 1958;22(5):876-886
6. Maier RF, Obladen M, Scigalla P, et al. The effect of epoetin β(recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. N Engl J Med. 1994;330(17):1173-1178
7. Ohls RK, Ehrenkranz RA, Das A, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics. 2004;114(5):1287-1291
8. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97(19):10526 -10531
9. Casals-Pascual C, Idro R, Gicheru N, et al. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. Proc Natl Acad Sci U S A. 2008;105(7):2634 -2639
10. Wang X, Zhu C, Wang X, et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem. 2004;91(4):900 -910
11. Chang YS, Mu D, Wendland M, et al. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res. 2005;58(1):106 -111
12. McPherson RJ, Demers EJ, Juul SE. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology. 2007;91(1):36-43
13. Wen TC, Rogido M, Peng H, Genetta T, Moore J, Sola A. Gender differences in long-term beneficial effects of erythropoietin given after neonatal stroke in postnatal day-7 rats. Neuroscience. 2006; 139(3):803- 811
14. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics. 2006;118(3). Available at: www.pediatrics.org/cgi/ content/full/118/3/e635
15. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8(8):495-505
16. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95(9):2983-2989
17. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress: a clinical and electroencephalographic study. Arch Neurol. 1976;33(10):696 -705
18. Thompson CM, Puterman AS, Linley LL, et al. The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. Acta Paediatr. 1997;86(7):757-761
19. Amiel-Tison C, Ellison P. Birth asphyxia in the full-term newborn: early assessment and outcome. Dev Med Child Neurol. 1986;28(5):671- 682
20. Bao XL, Yu RJ, Li ZS. 20-item neonatal behavioral neurological assessment used in predicting prognosis of asphyxiated newborn. Chin Med J (Engl). 1993;106(3):211-215
21. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39(4):214 -223
22. Bayley N. Bayley Scales of Infant Development, Second Edition. San Antonio, TX: The Psychological Corporation; 1993
23. Eicher DJ, Wagner CL, Katikaneni LP, et al. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. Pediatr Neurol. 2005;32(1):11-17
24. Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res. 2007;61(4):451- 455
25. Villa P, van Beek J, Larsen AK, et al. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab. 2007;27(3):552-563
26. Keller M, Yang J, Griesmaier E, et al. Erythropoietin is neuroprotective against NMDA-receptormediated excitotoxic brain injury in newborn mice. Neurobiol Dis. 2006;24(2):357-366
27. US Food and Drug Administration. Early communication about an ongoing safety review: epoetin alfa. Available at: www.fda.gov/cder/drug/early-comm/ epoetin-alfa.htm. Accessed February 20, 2009
28. Juul SE, McPherson RJ, Farrell FX, Jolliffe L, Ness DJ, Gleason CA. Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate. 2004;85(2):138 -144
29. Xenocostas A, Cheung WK, Farrell F, et al. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol. 2005;61(3):189 -195
30. Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr Res. 1999;46(5):543-547
31. Chen N, Mao J, Du Y. Erythropoietin levels in serum and cerebrospinal fluid of neonates with hypoxic-ischemic encephalopathy. Chin J Contemp Pediatr. 2005;7(2):107-111
32. Melo AM, Costa MT, Porta V, Vaz FA. Clinical pharmacokinetics of lyophilized recombinant human erythropoietin-α following single-dose subcutaneous administration in premature newborns. J Matern Fetal Neonatal Med. 2005;17(1):55-58
33. Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry. 2004;9(1):42-54
34. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther. 2001;298(2): 820-824
35. Statler PA, McPherson RJ, Bauer LA, Kellert BA, Juul SE. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res. 2007;61(6):671- 675
36. Sirén AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A. 2001;98(7):4044-4049
37. Gonzalez FF, McQuillen P, Mu D, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci. 2007;29(4 -5):321-330
38. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003;198(6): 971-975
39. Zhu C, Wang X, Xu F, et al. The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ. 2005;12(2):162-176
40. Ferriero DM. Neonatal brain injury. N Engl J Med. 2004;351(19):1985-1995
41. Edwards AD, Yue X, Cox P, et al. Apoptosis in the brains of infants suffering intrauterine cerebral injury. Pediatr Res. 1997;42(5):684-689
42. Zhu C, Wang X, Huang Z, et al. Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ. 2007;14(4):775-784
43. Raber J, Fan Y, Matsumori Y, et al. Irradiation attenuates neurogenesis and exacerbates ischemiainduced deficits. Ann Neurol. 2004;55(3):381-389
44. Naylor AS, Bull C, Nilsson MK, et al. Voluntary running rescues adult hippocampal neurogenesis after irradiation of the young mouse brain. Proc Natl Acad Sci U S A. 2008;105(38):14632-14637
45. Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008;122(2):383-391